Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - CUMBERLAND PHARMACEUTICALS INC | a2019-10kxexhibit321.htm |
| EX-31.2 - EX-31.2 - CUMBERLAND PHARMACEUTICALS INC | a2019-10kxexhibit312.htm |
| EX-31.1 - EX-31.1 - CUMBERLAND PHARMACEUTICALS INC | a2019-10kxexhibit311.htm |
| EX-10.15 - EX-10.15 - CUMBERLAND PHARMACEUTICALS INC | a2019-10kxexhibit1015j.htm |
| EX-10.14 - EX-10.14 - CUMBERLAND PHARMACEUTICALS INC | a2019-10kxexhibit1014m.htm |
| EX-10.13 - EX-10.13 - CUMBERLAND PHARMACEUTICALS INC | a2019-10kxexhibit1013l.htm |
| EX-10.12 - EX-10.12 - CUMBERLAND PHARMACEUTICALS INC | a2019-10kxexhibit1012m.htm |
| EX-10.11 - EX-10.11 - CUMBERLAND PHARMACEUTICALS INC | a2019-10kxexhibit1011a.htm |
| 10-K - 10-K - CUMBERLAND PHARMACEUTICALS INC | cpix-20191231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Cumberland Pharmaceuticals Inc.
Nashville, Tennessee
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-221402) and Form S-8 (No. 333-164376) of Cumberland Pharmaceuticals Inc. of our report dated March 20, 2020, relating to the consolidated financial statements and financial statement schedule which appears in this Form 10-K.
/s/ BDO USA, LLP
Nashville, Tennessee
March 20, 2020